Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Hepatogastroenterology ; 49(48): 1582-6, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12397741

RESUMO

BACKGROUND/AIMS: Gastrointestinal motility disorders are often present in diabetic patients. Even if this problem has been attributed to autonomic neuropathy, the pathophysiological mechanisms responsible are not completely defined. Aim of our study was to evaluate the effect of eradication of small-intestine bacterial overgrowth on oro-cecal transit time in diabetic patients in order to identify a possible role of bacterial overgrowth on dysmotility. METHODOLOGY: We selected among 74 diabetic patients who underwent H2-lactulose breath test, 21 subjects (13M, 8F, mean age 43.7 years, 11 with type 1 and 10 with type 2 diabetes) affected by bacterial overgrowth and delayed oro-cecal transit time and with normal cardiovascular autonomic test. Patients were treated with rifaximin and underwent a control breath test. Data were analyzed using paired-data t-test. RESULTS: Three patients still showed bacterial overgrowth, 5 persistent delayed transit time without bacterial overgrowth; 13 patients (62%) showed a significant (P < 0.001) reduction of on oro-cecal transit time without bacterial overgrowth. CONCLUSIONS: Our results show that bacterial overgrowth may contribute to the delay of intestinal transit as confirmed by its significant improvement after eradication therapy.


Assuntos
Anti-Infecciosos/uso terapêutico , Infecções Bacterianas/tratamento farmacológico , Diabetes Mellitus/fisiopatologia , Trânsito Gastrointestinal , Intestino Delgado/microbiologia , Rifamicinas/uso terapêutico , Adulto , Infecções Bacterianas/diagnóstico , Testes Respiratórios , Estudos de Casos e Controles , Feminino , Humanos , Lactulose/metabolismo , Masculino , Pessoa de Meia-Idade , Rifaximina , Resultado do Tratamento
2.
Ann Ital Med Int ; 17(3): 157-65, 2002.
Artigo em Italiano | MEDLINE | ID: mdl-12402663

RESUMO

The ingestion of probiotics is associated with various beneficial effects on human health and modifies the physiological homeostasis of the intestinal flora. Probiotics are microorganisms with some particular characteristics: human origin, safety in human use, bile and acid resistance, survival in the intestine, at least temporary colonization of the human gut, adhesion to the mucosa and bacteriocine production. Thanks to these characteristics, probiotics block the invasion of human intestinal cells by the enteroinvasive bacteria. Furthermore, they should be able to stimulate and modulate the intestinal immune response, and to protect and stabilize the mucosal barrier. Finally, the efficacy of probiotics should be evident and documented with valid studies. All their properties should be maintained during processing and storage. Probiotics are usually used to protect the host from pathogens. With regard to this, they are useful in the prevention of antibiotic and traveler's diarrhea and they may play a role in the management of gastric Helicobacter pylori infection. Furthermore, their efficacy in the treatment of infectious diarrhea, in inflammatory bowel diseases, in pouchitis and in food allergy has been shown. Probiotics can improve the symptoms of irritable bowel syndrome and of lactose malabsorption. Finally, it has been suggested that such microorganisms may play a role in the prevention of carcinogenesis and of tumor growth.


Assuntos
Enteropatias/terapia , Probióticos/uso terapêutico , Adulto , Anticarcinógenos/uso terapêutico , Bifidobacterium , Humanos , Hipercolesterolemia/terapia , Hipersensibilidade/prevenção & controle , Hipersensibilidade/terapia , Recém-Nascido , Doenças Inflamatórias Intestinais/terapia , Enteropatias/prevenção & controle , Neoplasias Intestinais/prevenção & controle , Neoplasias Intestinais/terapia , Intestinos/microbiologia , Lactobacillus , Intolerância à Lactose/terapia , Síndromes de Malabsorção/terapia , Probióticos/administração & dosagem , Ensaios Clínicos Controlados Aleatórios como Assunto , Infecções Urinárias/prevenção & controle
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA